480 related articles for article (PubMed ID: 29649743)
21. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
Bhattacharyya B; Panda D; Gupta S; Banerjee M
Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
[TBL] [Abstract][Full Text] [Related]
22. Anti-Microtubule Drugs.
Florian S; Mitchison TJ
Methods Mol Biol; 2016; 1413():403-21. PubMed ID: 27193863
[TBL] [Abstract][Full Text] [Related]
23. Molecular modelling studies on Arylthioindoles as potent inhibitors of tubulin polymerization.
Coluccia A; Sabbadin D; Brancale A
Eur J Med Chem; 2011 Aug; 46(8):3519-25. PubMed ID: 21621885
[TBL] [Abstract][Full Text] [Related]
24. 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents.
Chang JY; Hsieh HP; Chang CY; Hsu KS; Chiang YF; Chen CM; Kuo CC; Liou JP
J Med Chem; 2006 Nov; 49(23):6656-9. PubMed ID: 17154496
[TBL] [Abstract][Full Text] [Related]
25. A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.
Nguyen TL; McGrath C; Hermone AR; Burnett JC; Zaharevitz DW; Day BW; Wipf P; Hamel E; Gussio R
J Med Chem; 2005 Sep; 48(19):6107-16. PubMed ID: 16162011
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.
Wang G; Li C; He L; Lei K; Wang F; Pu Y; Yang Z; Cao D; Ma L; Chen J; Sang Y; Liang X; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2014 Apr; 22(7):2060-79. PubMed ID: 24629450
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel and potent small-molecule inhibitors of tubulin with antitumor activities by virtual screening and biological evaluations.
Liu G; Jiao Y; Huang C; Chang P
J Comput Aided Mol Des; 2019 Jul; 33(7):659-664. PubMed ID: 31165955
[TBL] [Abstract][Full Text] [Related]
28. Hydropathic analysis and biological evaluation of stilbene derivatives as colchicine site microtubule inhibitors with anti-leukemic activity.
Tripathi A; Durrant D; Lee RM; Baruchello R; Romagnoli R; Simoni D; Kellogg GE
J Enzyme Inhib Med Chem; 2009 Dec; 24(6):1237-44. PubMed ID: 19912057
[TBL] [Abstract][Full Text] [Related]
29. Tubulins - the target for anticancer therapy.
Vindya NG; Sharma N; Yadav M; Ethiraj KR
Curr Top Med Chem; 2015; 15(1):73-82. PubMed ID: 25579568
[TBL] [Abstract][Full Text] [Related]
30. Tubulin inhibitors: a patent survey.
Nepali K; Ojha R; Sharma S; Bedi PM; Dhar KL
Recent Pat Anticancer Drug Discov; 2014 May; 9(2):176-220. PubMed ID: 23746164
[TBL] [Abstract][Full Text] [Related]
31. Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
Zhao W; He L; Xiang TL; Tang YJ
Eur J Med Chem; 2019 May; 170():73-86. PubMed ID: 30878833
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy.
Hawash M
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551271
[TBL] [Abstract][Full Text] [Related]
33. Recent development and SAR analysis of colchicine binding site inhibitors.
Chen J; Liu T; Dong X; Hu Y
Mini Rev Med Chem; 2009 Sep; 9(10):1174-90. PubMed ID: 19817710
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of imidazo[2,1-b][1,3,4]thiadiazole-linked oxindoles as potent tubulin polymerization inhibitors.
Kamal A; Rao MP; Das P; Swapna P; Polepalli S; Nimbarte VD; Mullagiri K; Kovvuri J; Jain N
ChemMedChem; 2014 Jul; 9(7):1463-75. PubMed ID: 24715721
[TBL] [Abstract][Full Text] [Related]
35. Synthesis, biological evaluation and molecular modeling of 1,2,3-triazole analogs of combretastatin A-1.
Akselsen OW; Odlo K; Cheng JJ; Maccari G; Botta M; Hansen TV
Bioorg Med Chem; 2012 Jan; 20(1):234-42. PubMed ID: 22137934
[TBL] [Abstract][Full Text] [Related]
36. Binding of dihydroxynaphthyl aryl ketones to tubulin colchicine site inhibits microtubule assembly.
Gutierrez E; Benites J; Valderrama JA; Calderon PB; Verrax J; Nova E; Villanelo F; Maturana D; Escobar C; Lagos R; Monasterio O
Biochem Biophys Res Commun; 2015 Oct; 466(3):418-25. PubMed ID: 26365353
[TBL] [Abstract][Full Text] [Related]
37. An overview of tubulin inhibitors that interact with the colchicine binding site.
Lu Y; Chen J; Xiao M; Li W; Miller DD
Pharm Res; 2012 Nov; 29(11):2943-71. PubMed ID: 22814904
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents.
Ruan BF; Lu X; Tang JF; Wei Y; Wang XL; Zhang YB; Wang LS; Zhu HL
Bioorg Med Chem; 2011 Apr; 19(8):2688-95. PubMed ID: 21440448
[TBL] [Abstract][Full Text] [Related]
39. QSAR and 3D-QSAR models in the field of tubulin inhibitors as anticancer agents.
Marzaro G; Chilin A
Curr Top Med Chem; 2014; 14(20):2253-62. PubMed ID: 25434357
[TBL] [Abstract][Full Text] [Related]
40. New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies.
De Martino G; Edler MC; La Regina G; Coluccia A; Barbera MC; Barrow D; Nicholson RI; Chiosis G; Brancale A; Hamel E; Artico M; Silvestri R
J Med Chem; 2006 Feb; 49(3):947-54. PubMed ID: 16451061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
